General MM,   Patients eligible for transplant

Can MRD guide treatment of post-transplant dara-KRd consolidation?

L: English

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Luciano J. Costa, University of Alabama at Birmingham, Vestavia, US, answers the question: Can the minimal residual disease (MRD) status guide combination treatment of daratumumab (dara), carfilzomib, lenalidomide and dexamethasone (KRd) post-transplant consolidation?

In this video Dr Costa discusses the quadruplet of dara-KRd as induction followed by transplant and dara-KRd consolidation, and the use of MRD assessment as an endpoint as well as a decision-making tool.